We are a fast-growing, science-led, research and development company. The foundation of AIBR is to transform the future of healthcare by unlocking the power of science to prevent and cure cancer through pioneering interdisciplinary research, translating new knowledge into better prevention and treatment towards improved patients care. Our platform enables our collaborators to discover high-quality, novel molecules more rapidly, at lower cost with a higher likelihood of success. We harnessing our inhouse algorithms for the discovery of novel small molecule and peptide theraputics against client targets. We are proud of our drug discovery program to be leading this digital revolution by constantly developing an intensive discovery and validation pipelines for potent targeted leads.
May 31, 2023 – FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer. The Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and...
January 26, 2023 – FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. The Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a &...
July 31, 2023 - The Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent endometrial cancer (EC) that is mismatch repair deficient (dMMR), a...